Related Experiment Video

Updated: Jun 3, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine

Michelle G Goveia1, Max Ciarlet, Katey E Owen

  • 1Merck & Co., Inc., West Point, Pennsylvania 19486, USA. michelle_goveia@merck.com

Annals of the New York Academy of Sciences
|March 26, 2011
PubMed

Insights

RotaTeq, a pentavalent oral rotavirus vaccine, effectively prevents severe rotavirus gastroenteritis (RVGE) in children. Postlicensure studies confirm its safety and significant impact on reducing RVGE incidence and healthcare costs globally.

Area of Science:

  • Vaccinology
  • Pediatric Infectious Diseases
  • Gastroenterology

Background:

  • Rotavirus gastroenteritis (RVGE) is a primary cause of severe diarrhea in children globally.
  • Existing rotavirus vaccines have varying efficacy and coverage.
  • The need for a broadly protective and safe rotavirus vaccine is critical.

Purpose of the Study:

  • To provide an overview of the development, clinical evaluation, and postlicensure impact of RotaTeq™.
  • To highlight the unique design and manufacturing of the pentavalent oral rotavirus vaccine.
  • To assess the efficacy and safety of RotaTeq in diverse populations.

Main Methods:

  • Development of five human-bovine reassortant rotavirus strains.
  • Extensive clinical trials, including one of the largest vaccine trials conducted.
  • Postlicensure surveillance and safety studies in large populations.

Main Results:

  • RotaTeq™ contains five human-bovine reassortant rotavirus strains targeting common serotypes (G1-G4, P1A[8]).
  • Clinical trials demonstrated the vaccine to be well-tolerated and highly efficacious against severe RVGE.
  • Postlicensure studies in the U.S. showed no identified safety signals and a significant reduction in RVGE.

Conclusions:

  • RotaTeq™ offers broad protection against the most common rotavirus serotypes.
  • The vaccine has proven effective and safe in clinical trials and real-world postlicensure use.
  • RotaTeq™ has substantially reduced the burden of RVGE and associated medical costs since its 2006 licensure.

More Related Videos

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Real Time RT-PCR02:57

Real Time RT-PCR

Real-time reverse transcription-polymerase chain reaction, or Real-time RT-PCR, is an analytical tool used to determine the expression level of target genes. The method involves converting mRNA to complementary DNA with the help of an enzyme known as reverse transcriptase, followed by the PCR amplification of the cDNA. These two processes can be performed simultaneously in a single tube or separately as a two-step reaction.
The real-time quantification of the number of amplified products is...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Vaccinations01:51

Vaccinations

Overview